严重高血压与血栓性微血管病变:需要针对病原体的向治疗
Manuel Praga1, Fernando Caravaca-Fontán2, Teresa Cavero3
1Department of Medicine, Complutense University, Madrid, Spain.
Kidney international
|November 22, 2025
概括
恶性高血压与血栓性微血管病变需要紧急诊断. 本综述强调了临床和组织学线索,以早期识别补充介导的血栓性微血管病变,从而能够迅速使用补充抑制剂进行治疗.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 血液学 血液学 血液学
- 遗传学 是一个遗传学.
背景情况:
- 恶性高血压与急性损伤是危及生命的,风险功能损失.
- 血栓式微血管病变使诊断和治疗复杂化.
- 补充介导的血栓性微血管病常常呈现出严重的高血压,模仿基本高血压.
研究的目的:
- 审查临床和组织学数据,以早期诊断补充介导的血栓性微血管病变.
- 在基因测试结果之前指导开始补充剂阻断剂.
- 发现病原,诊断和治疗方面的研究缺口.
主要方法:
- 对临床和组织学数据的审查.
- 在区分高血压类型的诊断挑战的分析.
- 讨论补充基因测试及其局限性.
主要成果:
- 严重的高血压可以诱导血栓性微血管病变的病变.
- 早期识别补充介导的血栓性微血管病变至关重要.
- 临床和组织学特征可以表明在等待遗传确认之前的诊断.
结论:
- 及时诊断补充介导的血栓性微血管病变对于及时开始治疗至关重要.
- 需要进一步的研究,以解决了解和管理这种情况的差距.
- 临床和组织学评估可以指导早期治疗决策.
相关概念视频
Venous Thrombosis III: Interprofessional Care
268
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
268
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
427
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
427
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
419
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
419
Hypertension IV: Drug Therapy and Lifestyle Modifications
595
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
595
Pulmonary Hypertension: Classification and Pathogenesis
547
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
547
Hypertension I: Introduction
720
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
720


